Brain scans reveal how experimental drug LG-0317 targets serotonin transporters

NCT ID NCT07708428

Not yet recruiting Knowledge-focused Sponsor: LinGang Laboratory Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This early-phase study uses PET/CT brain scans to see how much of a single dose of LG-0317 tablets binds to serotonin transporters (SERT) in the brains of healthy men aged 18 to 45. Researchers will also measure drug levels in the blood and monitor for side effects. The goal is to understand the relationship between dose, brain occupancy, and safety before testing the drug in people with medical conditions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LG-0317 tablets
What this could lead to: If successful, this study could help determine the right dose of LG-0317 for future trials targeting conditions linked to serotonin, such as depression or anxiety.
What could go wrong: This is a very early, small study in healthy volunteers, so results may not predict effects in patients. The drug may also cause side effects not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS (HV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS (HV)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.